*Oxford National Institute for Health Research (NIHR), Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; †Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; ‡Internal Medicine Department, Musculoskeletal Research Unit and Red Tematica de Investigacion Cooperativa en Envejecimiento y Fragilidad (RETICEF), Fundacio Institut Mar d'Investigacions Mediques (FIMIM), and Instituto de Salud Carlos III, Barcelona, Spain; §Institut d'Investigacio en Atencio Primaria (IDIAP), Jordi Gol-Primary Care Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain; ‖Department of Internal Medicine and Infectious Diseases, Parc Salut Mar, Barcelona, Spain; ¶Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands; #Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands; **Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; ††Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands; and ‡‡Aalborg Hospital, Aalborg University, Aalborg, Denmark.
J Acquir Immune Defic Syndr. 2014 May 1;66(1):90-5. doi: 10.1097/QAI.0000000000000112.
Different studies have reported an association between HIV infection, antiretroviral therapies, and impaired bone metabolism, but data on their impact on fracture risk are scarce. We studied the association between a clinical diagnosis of HIV infection and fracture risk.
We conducted a case-control study using data from the Danish National Health Service registries, including 124,655 fracture cases and 373,962 age- and gender-matched controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression.
A total of 50 (0.40/1000) patients in the fracture group and 52 (0.14/1000) controls had an HIV diagnosis. The risk of any fracture was thus significantly increased among HIV-infected patients (age- and gender-matched OR = 2.89, 95% CI: 1.99 to 4.18). Similarly, significant increases in the risk of hip (OR = 8.99, 95% CI: 1.39 to 58.0), forearm (OR = 3.50, 95% CI: 1.26 to 9.72), and spine fractures (OR = 9.00, 95% CI: 1.39 to 58.1) were observed.
HIV infection is associated with an almost 3-fold increase in fracture risk compared with that of age- and gender-matched uninfected patients. HIV patients are also at an almost 9-fold higher risk of hip fracture.
不同的研究报告称 HIV 感染、抗逆转录病毒疗法与骨代谢受损之间存在关联,但关于它们对骨折风险影响的数据却很少。我们研究了 HIV 感染的临床诊断与骨折风险之间的关联。
我们使用丹麦国家卫生服务登记处的数据开展了一项病例对照研究,共纳入 124655 例骨折病例和 373962 名年龄和性别匹配的对照者。采用条件 logistic 回归估计比值比(OR)及其 95%置信区间(CI)。
骨折组中共有 50 例(0.40/1000)患者和对照组中有 52 例(0.14/1000)患者被诊断为 HIV 感染。与未感染 HIV 的患者相比,HIV 感染者发生任何骨折的风险均显著增加(年龄和性别匹配 OR=2.89,95%CI:1.99 至 4.18)。同样,髋部(OR=8.99,95%CI:1.39 至 58.0)、前臂(OR=3.50,95%CI:1.26 至 9.72)和脊柱骨折(OR=9.00,95%CI:1.39 至 58.1)的风险也显著增加。
与年龄和性别匹配的未感染患者相比,HIV 感染患者的骨折风险增加近 3 倍。HIV 患者髋部骨折的风险也增加近 9 倍。